How obesity drives colon cancer in mice
Led by assistant professor Rachel Perry , the research team studied mice with either implanted tumors or a genetic model of colon cancer. The researchers first examined the effects of a high-fat diet on the mice. Then they gave the mice one of two medications: either a drug that burns fat in the liver by acting as a controlled-release mitochondrial protonophore (CRMP), or metformin, the most commonly prescribed drug for diabetes worldwide.
The research team found that high levels of insulin was the link between obesity and colon cancer, Perry said. Insulin increases the uptake of glucose in tumors, driving tumor growth. The researchers also discovered that both drugs reduced insulin levels and slowed tumor growth in the mice.
“ This study is the first to prove that high insulin levels resulting from obesity drive colon cancer by increasing glucose uptake in these models,” said Perry. While further research is needed to confirm if the findings apply to humans, the implication is that insulin-reducing therapies — either metformin, CRMP, or even exercise — could help slow or prevent colon cancer.
Original publication
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.